European Patent Office Backs AstraZeneca's Symbicort Patent
The European Patent Office has upheld the validity of the European combination patent for Swedish-U.K. drug maker AstraZeneca's asthma treatment Symbicort, which had faced a challenge by several generic manufacturers....To view the full article, register now.
Already a subscriber? Click here to view full article